Page last updated: 2024-09-05

sorafenib and artenimol

sorafenib has been researched along with artenimol in 5 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(artenimol)
Trials
(artenimol)
Recent Studies (post-2010) (artenimol)
6,5207305,25153048
6,5207305,2511,419279987

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Liu, Y; Xu, Z; Zhao, SJ1
Duan, X; Lv, Y; Wang, Z; Zhao, Y1
Guo, D; Hou, C; Liu, T; Wang, S; Yu, X1
Cui, Z; Jiang, T; Li, C; Li, L; Li, S; Ma, J; Qin, T; Shi, H; Wang, H; Yu, G1
Cui, Z; Jiang, T; Li, C; Li, L; Li, S; Ma, J; Qin, T; Shi, H; Tang, T; Wang, H; Xu, W; Zhou, H1

Reviews

1 review(s) available for sorafenib and artenimol

ArticleYear
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019

Other Studies

4 other study(ies) available for sorafenib and artenimol

ArticleYear
Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
    Life sciences, 2019, Dec-15, Volume: 239

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Reactive Oxygen Species; Receptors, LDL; Sorafenib

2019
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 126

    Topics: Antimalarials; Antineoplastic Agents; Artemisinins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Sorafenib; Up-Regulation

2020
Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.
    Journal of pharmacological sciences, 2022, Volume: 148, Issue:1

    Topics: Animals; Antineoplastic Agents; Artemisinins; Depression, Chemical; Drug Synergism; Drug Therapy, Combination; Energy Metabolism; Female; Ferroptosis; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Sorafenib

2022
Ferroptosis plays an essential role in the antimalarial mechanism of low-dose dihydroartemisinin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 148

    Topics: Animals; Antimalarials; Artemisinins; Cell Death; Female; Ferroptosis; Humans; Malaria; Mice; Mice, Inbred C57BL; Parasites; Piperazines; Reactive Oxygen Species; Sorafenib

2022